> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 3 Drug Firms Pay $447 Million Over ‘Price Fixing’
- URL: https://www.fdaweb.com/3-drug-firms-pay-447-million-over-price-fixing/
- Published: 2021-10-04T12:00:00.000Z
- Updated: 2026-09-14T17:17:34.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150280

Three generic drug makers — Taro Pharmaceuticals, Sandoz and Apotex —have agreed to pay $447 million to resolve alleged False Claims Act violations related to price fixing conspiracies involving various generic drugs. The Justice Department [alleges](https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-over-400-million-resolve-alleged-false-claims-act-liability?ref=fdaweb.com) that between 2013 and 2015, the companies paid and received compensation prohibited by the Anti-Kickback Statute through arrangements on price, supply and allocation of customers with other pharmaceutical manufacturers for certain generic drugs.

Under the agreement, Taro Pharmaceuticals will pay $213 million. “The Taro drugs allegedly implicated in this scheme address a wide variety of health conditions, and include etodolac, a nonsteroidal anti-inflammatory drug used to treat pain and arthritis, and nystatin-triamcinolone cream and ointment, a combination of an antifungal medicine and steroid used to treat certain kinds of skin infections,” the government says.  

Sandoz agreed to pay $185 million over allegations involving hypertension drug benazepril HCTZ, and skin corticosteroid clobetasol. And Apotex is paying $49 million for claims against its pravastatin, a drug used to treat high cholesterol and triglyceride levels.